Company Focus
Merck KGaA
Latest Merck KGaA News
Pharmaceutical
German pharma and technology group Merck KGaA has upgraded its full-year outlook after a second quarter in which its laboratory and semiconductor materials businesses more than covered a weakening pharmaceutical unit. Group net sales rose 3.4% to 5.4 billion euros ($6.24 billion), equal to organic growth of 4.1%, with currency effects clipping 1.1 percentage points off the reported figure. 6 August 2026
Related News
Insights
Company Spotlight
A San Carlos, California-based immunology biotech using nanobody-based multispecific biologics to target the IL-31 itch pathway, positioning its lead asset against the Dupixent franchise in atopic dermatitis and chronic pruritus.
Latest News & Features of interest to Merck KGaA
Biotechnology
US drugmaker Gilead Sciences raised the lower end of its 2026 sales guidance after second-quarter revenue beat expectations, driven by continued growth in HIV and oncology. 5 August 2026
Pharmaceutical
Boston, USA-based clinical-stage biotech CervoMed shares jumped 7.7% to $2.80 yesterday, after it announced that its investigational drug candidate, neflamapimod, has received an Innovation Passport designation to enter the UK’s Innovative Medicines and Health Products Regulatory Agency (MHRA) Accelerated Access Pathway (ILAP) for the development of neflamapimod in dementia with Lewy bodies (DLB). 5 August 2026
Biotechnology
Canada-based biotech Defence Therapeutics has announced a significant leadership change, appointing Dr Amie Phinney as president and chief executive (CEO), effective August 1, 2026. 4 August 2026
Biotechnology
Pathos AI, a US clinical-stage AI and technology company advancing its own pipeline of cancer therapies, announced a collaboration and co-exclusive licensing agreement with UK pharma major AstraZeneca. 4 August 2026
Pharmaceutical
US pharma major Pfizer raised the lower end of its full-year revenue forecast after second-quarter sales and adjusted earnings exceeded analyst expectations, with growth across its non-COVID portfolio offsetting sharp declines for Paxlovid (ritonavir) and Comirnaty. 4 August 2026
Pharmaceutical
US CNS-focused drugmaker Supernus Pharmaceuticals and addiction medicine specialist Indivior Pharmaceuticals have agreed an all-stock merger of equals, creating a company with pro forma annual revenue of around $2.2 billion. 4 August 2026
Pharmaceutical
German pharma and crop science major Bayer posted second-quarter 2026 sales of 10.87 billion euros ($12.39 billion), up 1.2% as reported and 2.2% on a currency- and portfolio-adjusted basis. Core earnings per share fell 16.7% to 0.95 euros ($1.08), held back by a normalization in tax expense and weaker earnings in the group's reconciliation line. 4 August 2026
Pharmaceutical
US pharma major Merck & Co, known as MSD outside the USA and Canada, reported second-quarter sales of $16.61 billion, up 5% year on year and 4% excluding currency, but a one-time charge tied to its Terns Pharmaceuticals takeover pushed the company to a loss on both reported and adjusted measures. 4 August 2026
Biotechnology
Swiss-domiciled oncology company BeOne Medicines has been awarded an Innovation Passport by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for BGB-B2033, an experimental bispecific antibody for hepatocellular carcinoma, the most common form of primary liver cancer. 4 August 2026
Pharmaceutical
In July 2025 the White House sent letters to 17 large drugmakers asking them to match, for American patients, the lowest prices they charge in other wealthy nations. A year on, all 17 have signed "most-favored-nation" (MFN) pricing deals. The administration says the group accounts for about 86% of the branded US market. 4 August 2026
Latest In Brief for Merck KGaA
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze